Prospective, open-label, uncontrolled pilot study to study safety and efficacy of sildenafil in systemic sclerosis–related pulmonary artery hypertension and cutaneous vascular complications

[1]  Z. Jing,et al.  The efficacy and safety of sildenafil in Chinese patients with pulmonary arterial hypertension , 2009, Hypertension Research.

[2]  V. Vidjak,et al.  One year efficacy and safety of oral sildenafil treatment in severe pulmonary hypertension. , 2009, Collegium Antropologicum.

[3]  F. Walz,et al.  Rasche Abheilung von akralen Ulzera bei systemischer Sklerodermie unter Sildenafil , 2008, Der Hautarzt.

[4]  R. Barst,et al.  Sildenafil for pulmonary arterial hypertension associated with connective tissue disease. , 2007, The Journal of rheumatology.

[5]  R. Gerszten,et al.  Sildenafil Improves Exercise Capacity and Quality of Life in Patients With Systolic Heart Failure and Secondary Pulmonary Hypertension , 2007 .

[6]  N. Sinha,et al.  Role of oral sildenafil in severe pulmonary arterial hypertension: clinical efficacy and dose response relationship. , 2007, International journal of cardiology.

[7]  Chen Wang,et al.  [Efficacy and safety of sildenafil therapy in pulmonary artery hypertension: a meta-analysis]. , 2007, Zhonghua yi xue za zhi.

[8]  T. Levien.  Phosphodiesterase Inhibitors in Raynaud's Phenomenon , 2006, The Annals of pharmacotherapy.

[9]  S. Malhotra,et al.  A randomized, placebo-controlled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension. , 2006, American heart journal.

[10]  M. Peberdy,et al.  Prognostic value of heart rate recovery in patients with heart failure. , 2006, American heart journal.

[11]  D. Abraham,et al.  Mechanisms and consequences of fibrosis in systemic sclerosis , 2006, Nature Clinical Practice Rheumatology.

[12]  T. Fleming,et al.  Sildenafil citrate therapy for pulmonary arterial hypertension. , 2005, The New England journal of medicine.

[13]  M. Böhm,et al.  Sildenafil in the Treatment of Raynaud’s Phenomenon Resistant to Vasodilatory Therapy , 2005, Circulation.

[14]  D. Pennell,et al.  Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study. , 2005, American journal of respiratory and critical care medicine.

[15]  S. Rosenkranz,et al.  Sildenafil improved pulmonary hypertension and peripheral blood flow in a patient with scleroderma-associated lung fibrosis and the raynaud phenomenon. , 2003, Annals of internal medicine.

[16]  S. Kimmel,et al.  Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. , 2003, Chest.

[17]  D. Isenberg,et al.  Pulmonary hypertension in autoimmune rheumatic diseases: where are we now? , 2002, Arthritis and rheumatism.

[18]  C. Narasimhan,et al.  A study of clinical efficacy of sildenafil in patients with primary pulmonary hypertension. , 2002, Indian heart journal.

[19]  Hiroshi Watanabe,et al.  Sildenafil for primary and secondary pulmonary hypertension , 2002, Clinical pharmacology and therapeutics.

[20]  M. Fujita,et al.  Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. , 2000, American journal of respiratory and critical care medicine.

[21]  G. Jackson,et al.  Effects of sildenafil citrate on human hemodynamics. , 1999, The American journal of cardiology.

[22]  G. Gemne,et al.  Diagnostics of hand-arm system disorders in workers who use vibrating tools. , 1997, Occupational and environmental medicine.

[23]  M. Meurer,et al.  [Fast and efficient healing of scleroderma-associated acral ulcers with sildenafil]. , 2008, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete.

[24]  P. Grenier,et al.  Pulmonary arterial hypertension is a major mortality factor in diffuse systemic sclerosis, independent of interstitial lung disease. , 2006, Arthritis and rheumatism.